chromosome 16 open reading frame 95Genealiases: []
Q-omics provides the consensus-scored C16orf95 profile across patient tissues and cancer cell-line models. C16orf95 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C16orf95 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, C16orf95 RNA expression shows 18,211 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where C16orf95 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C16orf95 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C16orf95 survival associations across molecular data types. C16orf95 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C16orf95 RNA expression–survival associations across cancer types. High C16orf95 expression shows unfavorable associations in KIRC, ACC, SKCM and KIRP, but favorable associations in LIHC and OV. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C16orf95 RNA expression.
This table summarizes C16orf95 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for C16orf95. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C16orf95 shows lower tumor expression in KICH and higher tumor expression in COAD, BLCA, HNSC, LUSC and KIRP. The COAD box plot shows higher C16orf95 RNA expression in tumor versus normal tissue (log2 FC = +0.452, t-test p < 0.001).
This table shows molecular features associated with C16orf95 in patient tissues and cancer cell lines. In patient samples, C16orf95 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, C16orf95 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and SOFT_TISSUE.
